Engineered immune cells take on hard-to-treat throat cancer
NCT ID NCT05587543
First seen Apr 25, 2026 · Last updated May 16, 2026 · Updated 4 times
Summary
This early-phase study tests two types of specially engineered immune cells (CAR-T and TCR-T) that target the Epstein-Barr virus (EBV) in patients whose nasopharyngeal cancer has come back or not responded to standard treatments. About 24 adults aged 18-75 with EBV-positive tumors will receive increasing doses to find the safest and most effective dose. The main goals are to check safety and measure how well the cells control the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.